GridAI Technologies Corp.
GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -2.01 | $85,876 | -$2M |
| 2026 Q1 | -0.82 | $38,208 | -$2M |
| 2025 Q4 | -0.73 | $36,251 | -$4M |
| 2025 Q3 | -0.75 | $0 | -$855,688 |
| 2025 Q2 | -0.21 | $0 | -$54,880 |
| 2025 Q1 | -0.28 | $0 | -$818,635 |
| 2024 Q4 |
| -2.59 |
| $0 |
| -$171,518 |
| 2024 Q3 | -0.59 | $0 | -$2M |